Terms: = Endocrine gland cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Clinical Outcome
40 results:
1. Immunoglobulins and serum proteins impair anti-tumor NK cell effector functions in malignant ascites.
Hrvat A; Benders S; Kimmig R; Brandau S; Mallmann-Gottschalk N
Front Immunol; 2024; 15():1360615. PubMed ID: 38646521
[TBL] [Abstract] [Full Text] [Related]
2. NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer.
Xiong Q; Zhou Y; Zhang S; Zhang Y; Xu Y; Yang Y; Zhou C; Zeng Z; Han J; Zhu Q
Cancer Med; 2023 May; 12(9):10961-10978. PubMed ID: 37062069
[TBL] [Abstract] [Full Text] [Related]
3. Improving Gemcitabine Sensitivity in Pancreatic cancer Cells by Restoring miRNA-217 Levels.
Panebianco C; Trivieri N; Villani A; Terracciano F; Latiano TP; Potenza A; Perri F; Binda E; Pazienza V
Biomolecules; 2021 Apr; 11(5):. PubMed ID: 33925948
[TBL] [Abstract] [Full Text] [Related]
4. Dysregulated miR-137 and its target egfr contribute to the progression of pituitary adenomas.
Wei D; Yu Z; Cheng Y; Jiawei H; Jian G; Hua G; Guilan D
Mol Cell Endocrinol; 2021 Jan; 520():111083. PubMed ID: 33246030
[TBL] [Abstract] [Full Text] [Related]
5. Comparison of thyroid hormone withdrawal and recombinant human thyroid-stimulating hormone administration for adjuvant therapy in patients with intermediate- to high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Inoue M; Nakamura K; Mizowaki T
Ann Nucl Med; 2020 Oct; 34(10):736-741. PubMed ID: 32643022
[TBL] [Abstract] [Full Text] [Related]
6. Anti-egfr chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial.
Liu Y; Guo Y; Wu Z; Feng K; Tong C; Wang Y; Dai H; Shi F; Yang Q; Han W
Cytotherapy; 2020 Oct; 22(10):573-580. PubMed ID: 32527643
[TBL] [Abstract] [Full Text] [Related]
7. Genome-wide DNA copy number profiling and bioinformatics analysis of ovarian cancer reveals key genes and pathways associated with distinct invasive/migratory capabilities.
Liu G; Ruan G; Huang M; Chen L; Sun P
Aging (Albany NY); 2020 Jan; 12(1):178-192. PubMed ID: 31895688
[TBL] [Abstract] [Full Text] [Related]
8. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by egfr/mTOR-PI3K/aurora kinase inhibitors.
Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
[TBL] [Abstract] [Full Text] [Related]
9. Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication.
Lippert J; Appenzeller S; Liang R; Sbiera S; Kircher S; Altieri B; Nanda I; Weigand I; Gehrig A; Steinhauer S; Riemens RJM; Rosenwald A; Müller CR; Kroiss M; Rost S; Fassnacht M; Ronchi CL
J Clin Endocrinol Metab; 2018 Dec; 103(12):4511-4523. PubMed ID: 30113656
[TBL] [Abstract] [Full Text] [Related]
10. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
Abdel-Wahab R; Varadhachary GR; Bhosale PR; Wang X; Fogelman DR; Shroff RT; Overman MJ; Wolff RA; Javle M
J Hematol Oncol; 2018 May; 11(1):71. PubMed ID: 29843755
[TBL] [Abstract] [Full Text] [Related]
11. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY
Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030
[TBL] [Abstract] [Full Text] [Related]
12. Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1α pathway to predict survival in resectable pancreatic cancer.
Qin R; Smyrk TC; Reed NR; Schmidt RL; Schnelldorfer T; Chari ST; Petersen GM; Tang AH
Br J Cancer; 2015 Feb; 112(3):514-22. PubMed ID: 25584484
[TBL] [Abstract] [Full Text] [Related]
13. outcome of gemcitabine plus molecular targeted agent for treatment of pancreatic cancer: a meta-analysis of prospective phase III studies.
Chen L; Zhang M; Luo S
Tumour Biol; 2014 Nov; 35(11):11551-8. PubMed ID: 25129442
[TBL] [Abstract] [Full Text] [Related]
14. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.
Matsuo K; Sheridan TB; Mabuchi S; Yoshino K; Hasegawa K; Studeman KD; Im DD; Rosenshein NB; Roman LD; Sood AK
Gynecol Oncol; 2014 Jun; 133(3):473-9. PubMed ID: 24674832
[TBL] [Abstract] [Full Text] [Related]
15. Anti-pancreatic cancer deliverables from sea: first-hand evidence on the efficacy, molecular targets and mode of action for multifarious polyphenols from five different brown-algae.
Aravindan S; Delma CR; Thirugnanasambandan SS; Herman TS; Aravindan N
PLoS One; 2013; 8(4):e61977. PubMed ID: 23613993
[TBL] [Abstract] [Full Text] [Related]
16. Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.
Gottschalk N; Lang S; Kimmig R; Singh M; Brandau S
BMC Cancer; 2012 Oct; 12():451. PubMed ID: 23036052
[TBL] [Abstract] [Full Text] [Related]
17. Vandetanib: in medullary thyroid cancer.
Frampton JE
Drugs; 2012 Jul; 72(10):1423-36. PubMed ID: 22715896
[TBL] [Abstract] [Full Text] [Related]
18. Ultraviolet enhances the sensitivity of pancreatic cancer cells to gemcitabine by activation of 5' AMP-activated protein kinase.
Adachi S; Yasuda I; Kawaguchi J; Yamauchi T; Nakashima M; Itani M; Nakamura M; Yoshioka T; Moriwaki H; Kozawa O
Biochem Biophys Res Commun; 2011 Oct; 414(1):53-9. PubMed ID: 21945432
[TBL] [Abstract] [Full Text] [Related]
19. Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma.
Trinh XB; Tjalma WA; Dirix LY; Vermeulen PB; Peeters DJ; Bachvarov D; Plante M; Berns EM; Helleman J; Van Laere SJ; van Dam PA
PLoS One; 2011; 6(7):e22469. PubMed ID: 21799864
[TBL] [Abstract] [Full Text] [Related]
20. Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome.
Adam P; Hahner S; Hartmann M; Heinrich B; Quinkler M; Willenberg HS; Saeger W; Sbiera S; Schmull S; Voelker HU; Ströbel P; Allolio B; Fassnacht M
Mod Pathol; 2010 Dec; 23(12):1596-604. PubMed ID: 20693985
[TBL] [Abstract] [Full Text] [Related]
[Next]
